Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- COLLAMEDIX INC
- Proposal award date
- 2023-09-01
- Contract end date
- 2024-07-31
- UEI
- GS4LCAYKAVC7
- Solicitation number
- PAR23-032
- Topic code
- NIAMS
Research abstract
1 Summary:2 There are ~300,000 rotator cuff (RC) repair procedures performed in the US annually at an estimated cost of3 $4B. Advanced degeneration of the RC causes pain and major disability. ‘Massive’ or ‘Irreparable’ (rt 5 cm) tears4 of RC consist of detachment between bone and tendon, and degeneration of tendon; thus, they cannot be repaired5 arthroscopically. Representing 40% of RC tears, they require costly and invasive muscle transfer or arthroplasty6 procedures. Overlay patches, dermal and otherwise, at best passively reinforce the underlying tendon and do7 not contribute to regeneration of tendon nor the enthesis. There is an unmet clinical need to develop regenerative8 implant products for patients suffering from irreparable tears.9 CollaMedix Inc. develops biotextile medical implants using high-strength pure-collagen threads produced by our
10 patented process of high-throughput electrochemical compaction. Spooled threads manufactured at CollaMedix
11 are braided by industrial braiding machines to obtain macroporous, highly biocompatible, resorbable scaffolds.
12 Collagen molecules are unidirectionally aligned within the scaffold threads, mimicking the native topography of
13 tendon, and imparting a tenoinductive effect on stem cells, as evidenced by the expression of tendon-specific
14 marker tenomodulin. Host collagen is templated parallel to these threads, resulting in an ordered tissue
15 deposition. Also, the crosslinking agent genipin that is used to stabilize threads polarizes macrophages to a pro-
16 regenerative phenotype.
17 We have designed such a scaffold that is infused with hydroxyapatite at one end, making it osteo-inductive on
18 that side while remaining teno-inductive on the other. This bi-phasic OsTend scaffold is load-bearing and
19 suturable, so it can bridge a large bone-tendon gap, while integrating with both bone and tendon. These
20 properties are ideal for repairing massively torn, degenerated tendons.
21 Based on this significant promise, CollaMedix Inc. proposes to test the feasibility of OsTend in a rabbit
22 model of chronic RC degeneration and repair. Rabbit infraspinatus tendons will be transected, allowed to
23 degenerate, and repaired with OsTends or left un-repaired. At 4 and 12 weeks post-implant, the tendons will be
24 mechanically tested and processed for histology. We hypothesize that the OsTend repaired group will have
25 stronger, thicker tendons and more normal histological characteristics, approaching that of intact controls.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
Research funding history
7 SBIR/STTR records share this UEI (2019–2024). Reported award amounts total $6,157,404. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services, National Science Foundation
Agency intelligence
Department of Health and Human Services
Back to SBIR/STTR Research Awards